8,774
Total Claims
$1.4M
Drug Cost
1,036
Beneficiaries
$1,382
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-9%
Cost per patient vs peers
$1,382 vs $1,524 avg
+5%
Brand preference vs peers
14.4% vs 13.7% avg
Brand vs Generic
86% generic
Brand: 1,263 claims · $1.3M
Generic: 7,511 claims · $170K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 656 | $713K |
| Rivaroxaban | 135 | $158K |
| Evolocumab | 139 | $144K |
| Sacubitril/Valsartan | 101 | $118K |
| Alirocumab | 76 | $56K |
| Empagliflozin | 17 | $17K |
| Dofetilide | 53 | $15K |
| Metoprolol Succinate | 934 | $15K |
| Rosuvastatin Calcium | 606 | $14K |
| Icosapent Ethyl | 29 | $12K |
| Carvedilol | 902 | $9,824 |
| Potassium Chloride | 400 | $9,021 |
| Flecainide Acetate | 168 | $8,003 |
| Nebivolol Hcl | 95 | $7,375 |
| Ezetimibe | 220 | $6,861 |
Prescribing Profile
57
Unique Drugs
$1.0M
Patient Profile
75
Avg Age
50%
Female
1.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data